Prognostic impact of Fusobacterium nucleatum in head and neck cancers: a meta-analysis of critical oncological outcomes Authors: Asuman Feda Bayrak, Mehmet Emin Arayici, Ozden Savas, Erdogan Ozgur, Aydan Ozkutuk, Enis Alpin Guneri Published: 2025 ABSTRACT BackgroundIt's a well-established fact that Fusobacterium nucleatum has been implicated in the pathogenesis and prognosis of several malignancies, but its role in head and neck cancers remains unclear. This systematic review and meta-analysis aimed to synthesize the evidence on the prognostic impact of Fusobacterium abundance in head and neck squamous cell carcinoma (HNSCC).MethodsA comprehensive literature search of PubMed/MEDLINE, Web of Science, Scopus, and Embase was performed from inception to January 1, 2000, to October 15, 2025. Studies evaluating the association between Fusobacterium and oncological outcomes in HNSCC were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease-specific survival (DSS) were pooled using random and fixed-effects models. Methodological quality was assessed with the Newcastle–Ottawa Scale (NOS), and reporting adhered to the PRISMA 2020 guidelines. The study protocol was prospectively registered in INPLASY (Registration ID: INPLASY2025110054).ResultsA total of six studies met the inclusion criteria, and five studies were included in the quantitative synthesis. The pooled analysis demonstrated a significant association between high Fusobacterium abundance and improved OS (random-effects model: HR = 0.60; 95% CI: 0.38–0.95, p = 0.03; I² = 37.6%; fixed-effects model: HR = 0.61; 95% CI: 0.43–0.87, p = 0.01; I² = 40.2%) and DSS (random-effects model: HR = 0.34; 95% CI: 0.19–0.61, p < 0.001; I² = 41.6%,; fixed-effects model: HR = 0.37; 95% CI: 0.24–0.56, p < 0.001; I² = 40.1%) in patients with HNSCC. Heterogeneity was low-to-moderate, and no significant small study effect was detected based on funnel plot inspection.ConclusionsThis meta-analysis suggests that Fusobacterium nucleatum abundance is significantly associated with better OS and DSS in patients with head and neck cancers. Fusobacterium nucleatum may be a potentially useful prognostic biomarker; however, this interpretation should be made with caution due to the limited evidence base, small number of studies, and residual heterogeneity. Taken together, further validation in large-scale, prospective studies is required and critical.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15404-1. Introduction Head and neck squamous cell carcinoma (HNSCC) is a major global malignancy, with approximately 890,000 new cases and 450,000 deaths recorded annually [1]. It represents a clinically heterogeneous group of tumors arising from the mucosal epithelium of the oral cavity, pharynx, and larynx, with distinct etiological subsets driven by tobacco/alcohol exposure or by oncogenic human papillomavirus (HPV) and Epstein–Barr virus (EBV) infection [2, 3]. Notably, HPV-positive HNSCC (especially oropharyngeal tumors) constitutes a biologically distinct subgroup associated with significantly better patient survival compared to HPV-negative disease [4]. This epidemiologic and molecular diversity underlines the need to explore novel factors in HNSCC pathogenesis and prognosis beyond the traditional risk factors and treatments. In recent years, the tumor microbiome has emerged as an important component of cancer biology. Growing evidence indicates that microbes residing in the human body – including within tumor tissues – can influence carcinogenesis, tumor progression, and metastasis [5]. Indeed, comprehensive surveys of multiple cancer types have revealed that each tumor type harbors a distinct intratumoral microbiota; bacteria are found living intracellularly in both cancer and immune cells, and their presence correlates with tumor characteristics and immune response variations [6]. In the context of HNSCC, the oral cavity’s abundant microbiome has drawn particular interest. Chronic periodontal inflammation (periodontitis) and dysbiosis of oral bacterial communities have been identified as independent risk factors for oral cancer, and Fusobacterium nucleatum (F. nucleatum (Fn)) – a key anaerobic bacterium in periodontal biofilms – is thought to contribute to this pro-tumorigenic inflammatory milieu [7]. These findings suggest that the microbiome may play a previously underappreciated role in modulating HNSCC development and outcomes. Among tumor-associated microbes, F. nucleatum has gained prominence as a potential mediator of cancer progression and prognosis. This oral commensal was first discovered to be highly prevalent within colorectal carcinomas [8], and subsequent studies in colorectal cancer (CRC) linked intratumoral F. nucleatum to aggressive disease features and worse patient outcomes [9]. In HNSCC, emerging data have similarly detected F. nucleatum DNA and cells in tumor specimens, hinting at a possible influence on tumor behavior. For example, high intratumoral Fusobacterium enrichment has been associated with an increased risk of cervical lymph node metastasis in patients with HNSCC [10]. However, the prognostic significance of F. nucleatum in head and neck tumors remains uncertain, as individual studies have yielded conflicting results. Intriguingly, several recent analyses even reported that HNSCC patients whose tumors harbored F. nucleatum had significantly longer cancer-specific survival and overall survival (OS) than those without F. nucleatum [11, 12], a finding contrary to the patterns observed in CRC and calling for further scrutiny. Therefore, despite the growing recognition of the tumor microbiome’s importance, the role of Fusobacterium nucleatum in HNSCC prognosis remains incompletely understood. As such, to address these outstanding questions and reconcile inconsistent findings, we conducted a systematic review and meta-analysis of published studies on HNSCC. The objective of this study was to critically evaluate the prognostic impact of F. nucleatum in head and neck cancers, focusing on critical oncological outcomes (such as survival and disease recurrence) in order to clarify its potential as a biomarker and inform future research and clinical management. Methods This systematic review with meta-analysis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [13]. The study protocol was prospectively registered in INPLASY (Registration ID: INPLASY2025110054, 10.37766/inplasy2025.11.0054). The study protocol was designed a priori to ensure methodological rigor, transparency, and reproducibility. All stages of the review—including literature search, study selection, data extraction, and statistical synthesis—were performed by two independent reviewers, with discrepancies resolved by consensus or consultation with a third investigator. A completed PRISMA 2020 checklist summarizing the reporting compliance of this study is provided in Table S1. The primary aim of this meta-analysis was to evaluate the prognostic role of Fusobacterium—particularly F. nucleatum—in patients with head and neck cancers, focusing on OS as the primary endpoint and other oncological outcomes (disease-specific survival [DSS], cancer-specific survival [CSS]) as secondary outcomes. Eligible studies were systematically identified through a structured search of major biomedical databases and reference lists of relevant publications. Quantitative synthesis was performed using random-effects and fixed effects meta-analysis models, and the overall certainty of evidence was assessed following established methodological frameworks. Literature search and data sources A comprehensive literature search was conducted to identify all relevant studies evaluating the prognostic role of Fusobacterium in head and neck cancers. The search strategy was developed in accordance with PRISMA 2020 recommendations and was designed to maximize sensitivity while maintaining specificity. We systematically searched the electronic databases PubMed/MEDLINE, Web of Science, Scopus, and Embase from January 1, 2000, to October 15, 2025, without language restrictions. In addition, we manually screened the reference lists of eligible articles and relevant reviews to identify any additional studies that may not have been captured in the electronic search. The search strategy combined controlled vocabulary (MeSH and Emtree terms) and free-text keywords using Boolean operators (AND, OR, NOT) related to Fusobacterium (e.g., “Fusobacterium nucleatum,” “Fusobacteriales”), head and neck cancers (e.g., “HNSCC,” “oral cancer,” “oropharyngeal cancer,” “laryngeal cancer”), and prognostic outcomes (e.g., “survival,” “mortality,” “disease-free survival,” “cancer-specific survival”). The core MeSH terms used included: For pathogen exposure: “Fusobacterium”[MeSH], “Fusobacterium nucleatum”[MeSH], “Fusobacteriales”, “oral microbiome”, “oral bacteria”. For cancer site: “Head and Neck Neoplasms”[MeSH], “Oropharyngeal Neoplasms”[MeSH], “Oral Neoplasms”[MeSH], “Laryngeal Neoplasms”[MeSH], “Hypopharyngeal Neoplasms”[MeSH], “Nasopharyngeal Neoplasms”[MeSH], “Tongue Neoplasms”[MeSH] For outcomes: “Prognosis”[MeSH], “Survival Analysis”[MeSH], “Disease-Free Survival”[MeSH], “Neoplasm Recurrence, Local”[MeSH], “Mortality”[MeSH], “Survival Rate”[MeSH], “Treatment Outcome”[MeSH]. A detailed search strategy for each database is provided in Supplementary Table S2. Duplicate records were removed using reference management software (Mendeley), and all titles and abstracts were independently screened by two reviewers. Study selection of interest All identified records were imported into a reference management software (Mendeley), and duplicate entries were removed prior to screening. Study selection was performed in two stages according to predefined eligibility criteria. In the first stage, two independent reviewers (AFB and MEA) screened the titles and abstracts of all retrieved citations to assess their relevance to the study question. In the second stage, the full texts of potentially eligible studies were reviewed in detail to determine final inclusion. Any discrepancies between the two reviewers were resolved through discussion or adjudication by a third senior reviewer. The study selection process followed PRISMA 2020 guidelines, and a PRISMA flow diagram (Fig. 1) was used to document the number of records identified, screened, assessed for eligibility, and included in the qualitative and quantitative syntheses. Records that did not meet the inclusion criteria were excluded with reasons documented (e.g., wrong population, no prognostic data, review articles, or non-original research). Only studies reporting prognostic associations between Fusobacterium (particularly F. nucleatum) and head and neck cancer outcomes were included in the final meta-analysis.Fig. 1PRISMA flow diagram illustrating the study selection process. A total of 367 records were identified through four major databases (PubMed/MEDLINE, Web of Science, Scopus, and Embase) and additional citation searching PRISMA flow diagram illustrating the study selection process. A total of 367 records were identified through four major databases (PubMed/MEDLINE, Web of Science, Scopus, and Embase) and additional citation searching Data extraction and quality assessment Data extraction was performed independently by two reviewers (AFB and MEA) using a standardized and piloted data extraction form. The following information was collected from each included study: author and year of publication, country, study design, sample size, tumor site, patient demographics (age, sex, HPV status, smoking status), detection method for Fusobacterium (e.g., qPCR, NGS, RNA-seq, ddPCR), definition of positivity or abundance cutoff, follow-up duration, outcomes of interest (OS, DSS, CSS, DFS), hazard ratios (HR) with corresponding 95% confidence intervals (CI), and covariates included in multivariable models when applicable. Where available, data from multivariate analyses were prioritized over univariate estimates. All data extractions were cross-checked by a third investigator to ensure accuracy and consistency. When necessary, corresponding authors of included studies were contacted for clarification or to obtain additional data. For studies presenting survival curves without reported HRs, estimates of HR and 95% CI were derived using the Tierney et al. method [14], based on Kaplan–Meier data and time-to-event distributions. The methodological quality of included studies was assessed using the Newcastle–Ottawa Scale (NOS) [15, 16] for cohort studies, evaluating selection, comparability, and outcome domains. Studies scoring ≥ 7 points were considered high quality. Quality assessment was conducted independently by two reviewers, and any discrepancies were resolved through consensus or, when necessary, by adjudication from a third investigator. Endpoints of interest for meta-analysis and PICOS framework The primary endpoint of this meta-analysis was OS among patients with head and neck cancers according to Fusobacterium status. OS was defined as the time from diagnosis (or treatment initiation) to death from any cause. Secondary endpoints included DSS and CSS, as reported by the individual studies. When available, multivariate-adjusted HRs with corresponding 95% confidence intervals (CIs) were extracted for each endpoint. Univariate estimates were used when adjusted HRs were not provided. This study was structured according to the PICOS framework (Population, Intervention/Exposure, Comparison, Outcomes, and Study Design), which guided the eligibility criteria and analytic approach: Population (P): Adult patients (≥ 18 years) with a histologically confirmed diagnosis of head and neck cancers, including oral cavity, oropharyngeal, hypopharyngeal, laryngeal, and nasopharyngeal squamous cell carcinomas. Intervention/Exposure (I): Presence or high abundance of Fusobacterium (particularly F. nucleatum) detected in tumor tissue or saliva samples by molecular methods (e.g., qPCR, NGS, ddPCR, RNA-seq). Comparison (C): Absence or low abundance of Fusobacterium. Outcomes (O): OS (primary); DSS or CSS (secondary). Study Design (S): Original human studies, including prospective or retrospective cohort studies, and case-control studies reporting time-to-event outcomes with HR and 95% CI or sufficient data to estimate these parameters. Studies not meeting the above criteria—such as case reports, narrative reviews, experimental animal studies, or studies without prognostic outcomes—were excluded. Statistical analysis All statistical analyses were performed in accordance with standard meta-analytic methodologies recommended for time-to-event outcomes. The effect measure of interest was the HR with corresponding 95% CIs. Whenever available, multivariate-adjusted HRs were extracted. When only univariate data were reported, these estimates were used in the primary meta-analysis, with sensitivity analyses planned to explore potential heterogeneity. The primary effect measure was the HR with 95% CIs for OS and secondary oncological outcomes. For each study, the natural logarithm of the HR and its corresponding standard error (SE) were calculated from the reported HRs and 95% CIs when necessary. All analyses were conducted using Stata (version 18.0; StataCorp, College Station, TX) and Review Manager (RevMan, version 5.4; Cochrane Collaboration). In this meta-analysis, we used both fixed-effect and random-effects models. The fixed-effect model assumes a single common true effect size across all studies, whereas the random-effects model allows true effects to vary between studies by accounting for underlying heterogeneity. In Stata, the meta-analysis was conducted using the metan command (metan loghr selog, random eform//label(namevar = study)///lcols(study n)///rcols(hr lci uci, header(“HR” “Lower 95% CI” “Upper 95% CI”))///effect(HR)///xlabel(0.1 0.5 1 2 5 10)///favours(“Fuso protective” “#Fuso harmful”) with the random-effect option, and results were expressed as pooled HRs with 95% CIs. In RevMan, meta-analysis was performed using the generic inverse-variance method, specifying HR as the effect size and fixed-effect weighting. In addition to pooled HRs with 95% CIs, 95% prediction intervals (PIs) were also calculated to estimate the expected range of effects in future studies, providing a more clinically interpretable measure of between-study variability. Forest plots were generated to display individual study estimates and the overall pooled effect. Statistical heterogeneity was assessed using Cochran’s Q test and quantified with the I² statistic. Although a fixed-effect model was chosen a priori, heterogeneity was carefully evaluated to ensure the appropriateness of model selection. An I² value above 50% or a significant Q test (p < 0.10) would have prompted sensitivity analyses and exploration of heterogeneity sources. Publication bias and small-study effects were evaluated using funnel plots. Sensitivity analyses (metainf) with fixed-effects were performed to assess the influence of individual studies on the pooled HR. All statistical tests were two-sided, and a p-value < 0.05 was considered statistically significant. Results The systematic search initially yielded a total of 367 records from four major electronic databases, including PubMed/MEDLINE (n = 89), Scopus (n = 103), Web of Science (n = 119), and Embase (n = 56). After the removal of 289 duplicates, 78 unique records remained for title and abstract screening. Of these, 66 were excluded based on predefined eligibility criteria. The remaining 12 reports were examined in detail, and seven reports could not be included in the study. These records were excluded because F. nucleatum was not reported as a separate variable (three reports), the oncological outcomes were not stratified according to F. nucleatum status, or no extractable effect size (e.g., hazard ratio, risk ratio, odds ratio) was provided or could be calculated (four reports). Ultimately, 5 studies met the inclusion criteria and were included in the quantitative synthesis in the first stage. In addition, 6 records were identified through citation searching, of which 1 study was eligible for qualitative synthesis. In total, 6 studies [11, 12, 17–20] were included in the review, and 5 [11, 12, 17–19] studies were included in the meta-analysis. The study selection process is summarized in Fig. 1. The methodological quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS). All six studies met the minimum quality threshold for inclusion in the quantitative synthesis. Four studies were rated as high quality (score ≥ 7) and two studies as moderate quality (score 4–6); no low-quality studies were identified. The mean NOS score was 7.3, reflecting overall good methodological rigor across the included evidence base. High scores were most consistently observed in the Selection and Outcome domains, whereas variability was noted in the Comparability domain, primarily related to the adjustment for confounding factors such as HPV status, smoking, and treatment modality. A detailed breakdown of quality assessment scores is provided in Fig. 2.Fig. 2Quality assessment of included studies using the Newcastle–Ottawa Scale (NOS). The methodological quality of all included studies was assessed using the Newcastle–Ottawa Scale (NOS) for cohort studies, covering selection (maximum 4 points), comparability (maximum 2 points), and outcome domains (maximum 3 points). Studies scoring ≥ 7 points were classified as high quality, and scores of 4–6 were classified as moderate quality. No low-quality studies were included. Scores of 7–9 were classified as high quality, 4–6 as moderate quality, and < 4 as low quality Quality assessment of included studies using the Newcastle–Ottawa Scale (NOS). The methodological quality of all included studies was assessed using the Newcastle–Ottawa Scale (NOS) for cohort studies, covering selection (maximum 4 points), comparability (maximum 2 points), and outcome domains (maximum 3 points). Studies scoring ≥ 7 points were classified as high quality, and scores of 4–6 were classified as moderate quality. No low-quality studies were included. Scores of 7–9 were classified as high quality, 4–6 as moderate quality, and < 4 as low quality Baseline characteristics of studies included in the systematic review A total of six studies published between 2020 and 2025, patients with head and neck squamous cell carcinoma (HNSCC), were included in the systematic review and meta-analysis. The studies were conducted across diverse geographical regions, including Asia (Hong Kong, Japan, India), Europe (France, UK, Italy), and South America (Brazil), reflecting substantial population heterogeneity. Most cohorts comprised oral cavity and oropharyngeal cancers, with varying proportions of HPV-negative and HPV-positive disease. The majority of studies used tumor tissue as the primary specimen, with Fusobacterium nucleatum detection performed using qPCR, RNA-sequencing, or ddPCR assays. One study also incorporated saliva-based 16 S rRNA sequencing for noninvasive assessment. Cut-off definitions for high vs. low abundance varied, including median relative abundance and cycle threshold (Ct) values. All studies evaluated at least one survival endpoint, including OS, DSS/CSS, DFS, or recurrence. Four studies performed multivariable Cox regression models, adjusting for relevant clinicopathologic factors such as tumor stage, HPV status, smoking, and alcohol use. Notably, Fusobacterium positivity was associated with a favorable prognosis in the majority of cohorts, though one study (Desai et al. 2022) reported a non-significant adverse association in early-stage tongue SCC. A detailed overview of study-level characteristics is provided in Table 1.Table 1Characteristics of included studies evaluating Fusobacterium nucleatum and prognosis in head and neck cancersAuthor, YearCountry/CohortCancer Type/SiteSample SizeSpecimen & MethodFn Definition (Cut-off)Outcomes AnalyzedKey Findings (Effect on Survival)Adjusted AnalysisChen et al., 2020 (Cancers)Hong Kong, 2015–2018HNSCC (oral cavity, oropharynx)68 patients (paired tumor & normal, oral rinse)Fresh frozen tumor tissue & oral rinse; 16 S rRNA gene sequencing + qPCRRelative abundance (Fn-high vs. Fn-low; threshold based on median RA)DSS, DFS, recurrenceFn-high associated with lower recurrence and improved DSS/DFS. DSS at 3y: 86.7% vs. 47.6% (Fn-high vs. Fn-low, p < 0.001).Multivariate Cox including smoking, stageNeuzillet et al., 2021 (Sci Rep)France (Institut Curie, 1990–2006)OSCC (cohort 1: mixed HNSCC incl. OSCC; cohort 2: OSCC only)Cohort 1: 122 (61 OSCC); Cohort 2: 90 OSCC; merged OSCC: 151Frozen tumor tissue; qPCR (16 S rRNA)Ct < 32 = Fn-positiveOS, RFS, MFSFn(+) associated with significantly longer OS, RFS, and MFS; independent prognostic factor for OS (HR ≈ 0.5, p < 0.01).Multivariate Cox including stage, LN status, smoking, alcoholDesai et al., 2022 (NAR Cancer)India (TMH/ACTREC) + TCGA validationEarly-stage tongue SCC (HPV-negative)Discovery: 108 TCGA HPV-neg; Validation: 74 tongue tumorsFresh frozen tongue tumors; RNA-seq & qPCRFn-high subgroup (based on RA > median, bioinformatics detection)OS, nodal metastasis, extracapsular spreadFn-high subgroup had worse OS (HR ≈ 1.67, NS in validation), more nodal metastases and extracapsular spread.KM survival, some regression; not consistently adjustedChander et al., 2024 (Cancer Comm.)UK/Italy + TCGA & MicroLearner cohortsHNSCC (mucosal; OSCC, oropharynx)TCMA: 155; MicroLearner: 175; Validation saliva cohortTumor transcriptomics (TCGA/TCMA), saliva 16 S sequencing; functional in vitro assaysRA cutoff (ROC-derived; tumor: 0.016; saliva: 2.760)OS, DSS, PFSFusobacterium detectability associated with better OS (HR 0.35, 95%CI 0.15–0.83) and DSS (HR 0.28, 95%CI 0.15–0.83). Saliva Fn-high associated with better PFS, esp. HPV-negative patients.Multivariate Cox incl. stage, HPV, smokingDatorre et al., 2025 (J Oral Microbiol)Brazil (Barretos Cancer Hospital, 2006–2012)HNSCC (oropharynx 70%, oral cavity 30%)94 FFPE tumorsddPCR (Fn-specific primers/probe)Detection of Fn DNA in tumorCSS, OS, DFSFn(+) in 59.6% of cases. Better CSS (5y: 61.5% vs. 39.1%, p = 0.013). Effect similar to HPV-positive patients.p16/HPV status considered; no full multivariate modelHamada et al., 2024Japan (TCGA-HNSCC & TCMA)HNSCC (mixed subsites)154 (TCGA)Tumor tissue; transcriptomic analysis (RNA-seqRelative abundance of Fusobacterium (median cut-off)OS (5-year), stratified by alcohol/smokingOverall: HR 0.72 (95% CI 0.44–1.18, p = 0.192) — multivariate 0.8840.497–1.574) Significant protective effect in non-smokers (HR 0.37, 95% CI 0.16–0.83) and non-drinkers (HR 0.28, 95% CI 0.10–0.80). Interaction p < 0.05.Multivariate Cox (adjusted for age, stage, smoking, alcohol). Effect modified by smoking/alcohol.HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, TCGA The Cancer Genome Atlas, qPCR quantitative polymerase chain reaction, FISH fluorescence in situ hybridization, FFPE formalin-fixed paraffin-embedded, HPV human papillomavirus Table 1Characteristics of included studies evaluating Fusobacterium nucleatum and prognosis in head and neck cancersAuthor, YearCountry/CohortCancer Type/SiteSample SizeSpecimen & MethodFn Definition (Cut-off)Outcomes AnalyzedKey Findings (Effect on Survival)Adjusted AnalysisChen et al., 2020 (Cancers)Hong Kong, 2015–2018HNSCC (oral cavity, oropharynx)68 patients (paired tumor & normal, oral rinse)Fresh frozen tumor tissue & oral rinse; 16 S rRNA gene sequencing + qPCRRelative abundance (Fn-high vs. Fn-low; threshold based on median RA)DSS, DFS, recurrenceFn-high associated with lower recurrence and improved DSS/DFS. DSS at 3y: 86.7% vs. 47.6% (Fn-high vs. Fn-low, p < 0.001).Multivariate Cox including smoking, stageNeuzillet et al., 2021 (Sci Rep)France (Institut Curie, 1990–2006)OSCC (cohort 1: mixed HNSCC incl. OSCC; cohort 2: OSCC only)Cohort 1: 122 (61 OSCC); Cohort 2: 90 OSCC; merged OSCC: 151Frozen tumor tissue; qPCR (16 S rRNA)Ct < 32 = Fn-positiveOS, RFS, MFSFn(+) associated with significantly longer OS, RFS, and MFS; independent prognostic factor for OS (HR ≈ 0.5, p < 0.01).Multivariate Cox including stage, LN status, smoking, alcoholDesai et al., 2022 (NAR Cancer)India (TMH/ACTREC) + TCGA validationEarly-stage tongue SCC (HPV-negative)Discovery: 108 TCGA HPV-neg; Validation: 74 tongue tumorsFresh frozen tongue tumors; RNA-seq & qPCRFn-high subgroup (based on RA > median, bioinformatics detection)OS, nodal metastasis, extracapsular spreadFn-high subgroup had worse OS (HR ≈ 1.67, NS in validation), more nodal metastases and extracapsular spread.KM survival, some regression; not consistently adjustedChander et al., 2024 (Cancer Comm.)UK/Italy + TCGA & MicroLearner cohortsHNSCC (mucosal; OSCC, oropharynx)TCMA: 155; MicroLearner: 175; Validation saliva cohortTumor transcriptomics (TCGA/TCMA), saliva 16 S sequencing; functional in vitro assaysRA cutoff (ROC-derived; tumor: 0.016; saliva: 2.760)OS, DSS, PFSFusobacterium detectability associated with better OS (HR 0.35, 95%CI 0.15–0.83) and DSS (HR 0.28, 95%CI 0.15–0.83). Saliva Fn-high associated with better PFS, esp. HPV-negative patients.Multivariate Cox incl. stage, HPV, smokingDatorre et al., 2025 (J Oral Microbiol)Brazil (Barretos Cancer Hospital, 2006–2012)HNSCC (oropharynx 70%, oral cavity 30%)94 FFPE tumorsddPCR (Fn-specific primers/probe)Detection of Fn DNA in tumorCSS, OS, DFSFn(+) in 59.6% of cases. Better CSS (5y: 61.5% vs. 39.1%, p = 0.013). Effect similar to HPV-positive patients.p16/HPV status considered; no full multivariate modelHamada et al., 2024Japan (TCGA-HNSCC & TCMA)HNSCC (mixed subsites)154 (TCGA)Tumor tissue; transcriptomic analysis (RNA-seqRelative abundance of Fusobacterium (median cut-off)OS (5-year), stratified by alcohol/smokingOverall: HR 0.72 (95% CI 0.44–1.18, p = 0.192) — multivariate 0.8840.497–1.574) Significant protective effect in non-smokers (HR 0.37, 95% CI 0.16–0.83) and non-drinkers (HR 0.28, 95% CI 0.10–0.80). Interaction p < 0.05.Multivariate Cox (adjusted for age, stage, smoking, alcohol). Effect modified by smoking/alcohol.HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, TCGA The Cancer Genome Atlas, qPCR quantitative polymerase chain reaction, FISH fluorescence in situ hybridization, FFPE formalin-fixed paraffin-embedded, HPV human papillomavirus Characteristics of included studies evaluating Fusobacterium nucleatum and prognosis in head and neck cancers Overall: HR 0.72 (95% CI 0.44–1.18, p = 0.192) — multivariate 0.884 0.497–1.574) Significant protective effect in non-smokers (HR 0.37, 95% CI 0.16–0.83) and non-drinkers (HR 0.28, 95% CI 0.10–0.80). Interaction p < 0.05. HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, TCGA The Cancer Genome Atlas, qPCR quantitative polymerase chain reaction, FISH fluorescence in situ hybridization, FFPE formalin-fixed paraffin-embedded, HPV human papillomavirus Across the six included studies, the median age of participants ranged from 58 to 63 years, with a male predominance consistent with the typical epidemiology of head and neck squamous cell carcinoma. Most cohorts involved advanced-stage disease (stage III–IV), although a subset of studies included early-stage cases. The most common tumor subsites were the oral cavity and oropharynx, with HPV positivity ranging from 11% to 25%, and a high prevalence of smoking history (52–64%), reflecting typical risk factor distributions in HNSCC populations. Tumor tissue was the most frequently used specimen type, complemented by saliva-based analyses in one study. Detection of Fusobacterium nucleatum relied primarily on qPCR and 16 S rRNA sequencing, with positivity rates ranging from 28% to 82%. Cut-off definitions varied, including median relative abundance and Ct values, and follow-up durations ranged from 36 to 60 months. Overall, these characteristics highlight a clinically and methodologically heterogeneous but representative population of patients with HNSCC, as summarized in Table 2.Table 2Clinical and methodological characteristics of included studiesAuthor (Year)CountryNAge (median/mean)Site(s)Stage distributionHPV (%)Smoking/AlcoholSample typeDetection methodFn positivityCut-offFollow-up (mo)Chen 2020Hong Kong6859 (mean)Oral cavity & oropharynxEarly + advanced21%64% smokerTumor + oral rinse16 S NGS49% Fn+Median RA36Neuzillet 2021France15163 (median)Oral cavityMajority stage III–IV12%58% smokerFFPE tumorqPCR (16 S rRNA)82% Fn+Ct ≤ 3260Desai 2022India (multicenter)7462 (median)Oral tongue SCCI–IV11%56% smokerTumorPathSeq (TCGA) + qPCR28% Fn+Detection vs. undetected60Chander 2024UK (TCMA + validation)33061 (median)HNSCC (mixed sites)III–IV25%55% smokerTumor/saliva16 S rRNA53% Fn+Median RA50Datorre 2025Brazil9458 (mean)Oropharynx (70%), oral cavity (30%)III–IV18%52% smokerFFPE tumorddPCR59.6% Fn+Detection vs. undetected60Hamada 2024Japan (TCGA/TCMA)15461 (median)HNSCC (mixed sites)I–IV20%60% smokerRNA-seqTaxonomic profiling50% highMedian RA60FN Fusobacterium nucleatum, HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, HPV human papillomavirus, FFPE formalin-fixed paraffin-embedded, qPCR quantitative polymerase chain reaction, TCGA The Cancer Genome Atlas Table 2Clinical and methodological characteristics of included studiesAuthor (Year)CountryNAge (median/mean)Site(s)Stage distributionHPV (%)Smoking/AlcoholSample typeDetection methodFn positivityCut-offFollow-up (mo)Chen 2020Hong Kong6859 (mean)Oral cavity & oropharynxEarly + advanced21%64% smokerTumor + oral rinse16 S NGS49% Fn+Median RA36Neuzillet 2021France15163 (median)Oral cavityMajority stage III–IV12%58% smokerFFPE tumorqPCR (16 S rRNA)82% Fn+Ct ≤ 3260Desai 2022India (multicenter)7462 (median)Oral tongue SCCI–IV11%56% smokerTumorPathSeq (TCGA) + qPCR28% Fn+Detection vs. undetected60Chander 2024UK (TCMA + validation)33061 (median)HNSCC (mixed sites)III–IV25%55% smokerTumor/saliva16 S rRNA53% Fn+Median RA50Datorre 2025Brazil9458 (mean)Oropharynx (70%), oral cavity (30%)III–IV18%52% smokerFFPE tumorddPCR59.6% Fn+Detection vs. undetected60Hamada 2024Japan (TCGA/TCMA)15461 (median)HNSCC (mixed sites)I–IV20%60% smokerRNA-seqTaxonomic profiling50% highMedian RA60FN Fusobacterium nucleatum, HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, HPV human papillomavirus, FFPE formalin-fixed paraffin-embedded, qPCR quantitative polymerase chain reaction, TCGA The Cancer Genome Atlas Clinical and methodological characteristics of included studies FN Fusobacterium nucleatum, HNSCC head and neck squamous cell carcinoma, OS overall survival, DSS disease-specific survival, CSS cancer-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, HPV human papillomavirus, FFPE formalin-fixed paraffin-embedded, qPCR quantitative polymerase chain reaction, TCGA The Cancer Genome Atlas Meta-analysis outcomes for overall-survival (OS) A total of three studies (Chander et al. 2024, Hamada et al. 2024, and Neuzillet et al. 2021) [12, 17, 19] were included in the meta-analysis evaluating the prognostic impact of Fusobacterium abundance on OS in head and neck cancers. The pooled analysis using a random-effects REML model demonstrated a significant survival benefit associated with high Fusobacterium abundance (HR = 0.60; 95% CI: 0.38–0.95, p = 0.03) (Fig. 3A). Between-study heterogeneity was low to moderate (I² = 37.7%, τ² = 0.06, Q = 3.35, p = 0.19) (Figure S1). The 95% PI ranged from approximately 0.25 to 1.41, suggesting that the direction of effect would likely remain consistent in future comparable studies. Sensitivity analysis using a fixed-effects inverse-variance model yielded similar results (HR = 0.61; 95% CI: 0.43–0.87, p = 0.01) (Fig. 3B). The funnel plot is also presented in Figure S2.Fig. 3Forest plots of overall-survival (OS) in patients with head and neck cancer according to Fusobacterium abundance. A Random-effects meta-analysis using the REML model. B Fixed-effects meta-analysis using the inverse-variance model Forest plots of overall-survival (OS) in patients with head and neck cancer according to Fusobacterium abundance. A Random-effects meta-analysis using the REML model. B Fixed-effects meta-analysis using the inverse-variance model Although the study by Desai et al. (2022) [20] was not included in the meta-analysis due to differences in study design and outcome reporting, it provides important insights into the biological heterogeneity of head and neck cancers. In a well-defined cohort of HPV-negative early-stage tongue squamous cell carcinoma, high Fusobacterium abundance was associated with a distinct pro-inflammatory tumor microenvironment characterized by increased expression of IL1B, IL6, and IL8. The authors observed that Fusobacterium-high and HPV-positive tumors were mutually exclusive, supporting the concept of biologically distinct molecular subtypes within this disease. Clinically, high Fusobacterium abundance was associated with a higher rate of extracapsular spread and a trend toward poorer OS (HR ≈ 1.67, p = 0.14). Meta-analysis outcomes for disease-specific survival (DSS) Three studies (Chen et al. 2020, Chander et al. 2024, and Datorre et al. 2025) [11, 12, 18] evaluated the prognostic role of Fusobacterium abundance in disease-specific (or cancer-specific) survival. The pooled analysis using a random-effects REML model demonstrated a significant survival benefit associated with high Fusobacterium abundance (HR = 0.34; 95% CI: 0.19–0.61, p < 0.001) (Fig. 4A). Heterogeneity was moderate (I² = 41.7%, τ² = 0.12, Q = 3.34, p = 0.19) (Figure S3), and the 95% CIs ranged from approximately 0.12 to 0.98, indicating consistent prognostic direction across studies. A fixed-effects inverse-variance model yielded similar results (HR = 0.37; 95% CI: 0.24–0.56, p < 0.001) (Fig. 4B), suggesting that high intratumoral Fusobacterium abundance is strongly associated with improved cancer-specific survival outcomes in patients with head and neck cancers. The funnel plot is also provided in Figure S4.Fig. 4Forest plots of disease-specific survival (DSS) in patients with head and neck cancer according to Fusobacterium abundance. A Random-effects meta-analysis using the REML model. B Fixed-effects meta-analysis using the inverse-variance model Forest plots of disease-specific survival (DSS) in patients with head and neck cancer according to Fusobacterium abundance. A Random-effects meta-analysis using the REML model. B Fixed-effects meta-analysis using the inverse-variance model Discussion HNSCC outcomes have been linked not only to traditional factors (such as HPV status and smoking) but also to the tumor microbiome, with Fusobacterium nucleatum emerging as a potential prognostic biomarker [7, 17]. In this systematic review and meta-analysis, we synthesized data from six studies (published 2020–2025 across Asia, Europe) evaluating the prognostic impact of intratumoral Fusobacterium in HNSCC. Patients whose tumors harbored Fusobacterium had markedly lower mortality risk. Such findings are notable, given that in other malignancies like colorectal cancer, Fusobacterium is generally linked to worse prognosis and tumor progression [7, 21]. Our study is the critical meta-analysis in HNSCC to highlight this paradoxical favorable association, emphasizing a novel facet of host-microbiome interactions in cancer. The meta-analysis for OS revealed a significant survival benefit associated with intratumoral Fusobacterium. Across three independent cohorts, patients with Fusobacterium-positive tumors experienced substantially better OS, with a pooled HR on the order of ~ 0.60, favoring Fusobacterium presence. In practical terms, this corresponds to roughly a 40% relative reduction in the risk of death among Fusobacterium-harboring patients, a finding consonant with reports of prolonged median survival (e.g. 60 months vs. 36 months in one study) for Fusobacterium-positive HNSCC [11]. Between-study heterogeneity in the OS analysis was low-to-moderate, indicating that this protective association was relatively consistent despite differences in study populations and methodologies. Notably, multiple groups in diverse geographic regions have independently observed improved overall outcomes in Fusobacterium-positive HNSCC, reinforcing the robustness of our result [7, 17, 18]. For instance, Neuzillet et al. (France) [17] found that F. nucleatum-positive oral cancer patients had significantly longer OS and lower recurrence rates than Fusobacterium-negative patients, with Fusobacterium status remaining an independent predictor of better survival in multivariate analysis. Similarly, Chen et al. (Hong Kong) [18] reported that Fusobacterium enrichment was associated with lower tumor stage, fewer recurrences, and improved survival outcomes. The convergence of evidence across these studies suggests that Fusobacterium might modulate tumor behavior or the host anti-tumor response in a manner that confers survival advantages in HNSCC. This consistency also lends credence to the idea that the association is biologically meaningful rather than a spurious finding or artifact of any single study. The protective effect of Fusobacterium was even more pronounced for CSS endpoints. In our meta-analysis of DSS/CSS (three studies), Fusobacterium-positive patients had roughly one-third the risk of HNSCC-specific mortality compared to Fusobacterium-negative patients. This translates to a two- to three-fold improvement in cancer-specific survival, highlighting Fusobacterium’s potential role in attenuating the aggressiveness of the disease. All included DSS studies [11, 12, 18] – despite originating from varied populations and using different detection techniques – consistently showed a favorable impact of Fusobacterium on cancer-specific outcome. For example, Chen et al. [18] documented significantly better 3-year disease-specific survival and a lower relapse rate in HNSCC patients with high F. nucleatum levels, mirroring our pooled findings. Likewise, a recent Brazilian cohort [11] using droplet digital PCR found that patients with intratumoral Fusobacterium had markedly improved 5-year survival (cancer-specific survival ~ 61.5% vs. 39.1% for Fusobacterium-negative, p = 0.013). That study’s authors emphasized that Fusobacterium presence correlated with longer survival, underscoring its potential as a prognostic marker in head and neck cancer. The magnitude and consistency of the DSS benefit observed across these studies strengthen the inference that Fusobacterium is associated with genuinely better cancer-specific outcomes, rather than being an incidental finding. Of note, Fusobacterium’s prognostic impact on HNSCC appears even stronger when focusing on deaths due to cancer itself, which may indicate a direct influence on tumor biology (e.g. slowing tumor progression or recurrence) in those harboring the bacterium. Despite the overall favorable pattern we observed, it is important to note that Fusobacterium’s prognostic influence may not be uniformly beneficial across all HNSCC subgroups. One included study by Desai et al. (2022) [20] focused on a well-defined subset of early-stage, HPV-negative tongue cancers and reported a notably different trend. In that cohort, tumors with high Fusobacterium burden exhibited a distinctly pro-inflammatory tumor microenvironment – characterized by overexpression of interleukins (IL1β, IL6, IL8) and other inflammatory mediators – alongside more aggressive pathological features such as higher rates of nodal metastasis and extracapsular spread. By contrast, HPV-positive oropharyngeal cancers—characterized by distinct virus-driven immune profiles—typically harbor lower F. nucleatum levels [22] and are generally less influenced by bacterial dysbiosis [23]. Clinically, these HPV-negative tongue cancer patients with abundant Fusobacterium had a trend toward poorer survival outcomes compared to those with low Fusobacterium levels (approximately 1.7-fold higher risk of death, although this did not reach statistical significance). This contrasting finding suggests that Fusobacterium’s prognostic impact may be context-dependent, varying with tumor site, stage, and the interplay with other etiological factors [7, 20]. Notably, in the Desai study, Fusobacterium-high tumors were almost entirely mutually exclusive with HPV-positive tumors, implying that Fusobacterium may defines a distinct molecular subtype of HNSCC in HPV-negative patients. In such tumors, Fusobacterium might be acting as a driver of an alternative inflammatory oncogenic pathway, which could potentially worsen outcomes in that specific setting. These context-dependent differences underscore that F. nucleatum’s tumor-promoting effects may be modulated by the immune microenvironment, differing between HPV-driven oropharyngeal tumors and HPV-negative, inflammation-associated oral tumors. Taken together, these results highlight that while Fusobacterium is generally associated with improved prognosis in HNSCC, there may be exceptions whereby certain subsets (e.g. HPV-unrelated oral cancers) do not derive a benefit – or could even be adversely impacted – by the presence of this bacterium. Methodologically, the studies included in our analysis were generally well-conducted, which bolsters confidence in the validity of our findings. All six studies met at least a moderate quality threshold on the Newcastle–Ottawa Scale, and four were graded as high quality – reflecting good selection of patients, comparability of groups, and adequate outcome assessment. Several investigations performed multivariable Cox regression adjustments for key prognostic factors (such as HPV status, smoking history, tumor stage, and treatment modalities), and notably Fusobacterium remained a significant prognostic factor even after controlling for these confounders. For example, Neuzillet et al. [17] reported that F. nucleatum positivity was independently associated with improved survival in a multivariate model, suggesting the bacterium’s effect is not merely surrogating for HPV or other favorable features. Nonetheless, we acknowledge some heterogeneity in the patient populations and methodologies of the included studies. The cohorts spanned different geographic regions with varied risk profiles (e.g. differing prevalence of HPV-positive oropharyngeal cancer and environmental exposures), and the detection of Fusobacterium was performed via diverse techniques – including 16 S rRNA gene sequencing, quantitative PCR, and droplet digital PCR – with no universal definition of “high” versus “low” Fusobacterium abundance [11, 17]. Such variability could contribute to differences in Fusobacterium positivity rates (which ranged from ~ 28% to >80% across studies) and effect size estimates, potentially limiting direct comparability between studies. We attempted to account for between-study variability using random-effects models; reassuringly, the observed heterogeneity was moderate and not statistically significant (for both OS and DSS meta-analyses), indicating that a true underlying association was reasonably consistent. Finally, while we did not detect obvious publication bias (the funnel plots appeared symmetric given the available studies and even unnecessary when there are fewer than 10 studies), the total number of studies was small (n = 5 in meta-analysis), so the power to rigorously assess bias is inherently limited. Caution is therefore warranted in over-interpreting the magnitude of the effect, and future studies will be valuable to confirm these findings in larger datasets. Our findings carry several important implications for both the scientific understanding of HNSCC and its potential clinical management. First, the consistent association of intratumoral Fusobacterium with improved survival raises the prospect that this bacterium could serve as a prognostic biomarker in HNSCC. In practical terms, assessing Fusobacterium status in tumor specimens (or possibly in oral samples, given one study’s use of saliva) might help identify patients – particularly among HPV-negative tumors – who have a more favorable underlying tumor biology and might experience better outcomes. However, this finding warrants careful interpretation, as the overall body of evidence remains modest, the study pool is small, and residual heterogeneity could not be fully resolved. This could one day inform risk stratification or personalized therapeutic decisions, although further validation is needed before clinical implementation. Second, the data prompt intriguing biological hypotheses: unlike in colorectal cancer, where F. nucleatum is known to promote tumor growth and immune evasion, in HNSCC, Fusobacterium may instead stimulate anti-tumor immune responses or create a tumor microenvironment that suppresses malignancy. Moreover, immune profiling studies have noted that Fusobacterium-positive HNSCCs tend to show an immune-activated phenotype; for example, one study found that Fusobacterium presence correlated with lower infiltration of M2 (immunosuppressive) macrophages and an immune gene expression signature indicative of a more anti-tumor response [17]. Similarly, Fusobacterium-high tumors have been linked to upregulation of pro-inflammatory cytokines and mediators (e.g. IL-1β, IL-6, IL-8 and MMP10), reflecting an immunologically active microenvironment [20]. These observations support the notion that Fusobacterium might paradoxically act as an adjuvant within the tumor, potentially enhancing immune-mediated tumor control in certain contexts. Finally, our review underscores the need for further research to harness these insights. Mechanistic studies are warranted to elucidate how Fusobacterium interacts with cancer cells and the immune system – for instance, determining whether Fusobacterium directly modulates immune checkpoints or tumor signaling pathways in HNSCC. In addition, future prospective studies or clinical trials could explore whether modifying the intratumoral microbiome (for example, through targeted antibiotics, probiotics, or other microbiome-altering interventions) can influence patient outcomes in head and neck cancer. If a causal role is established, it opens the door to innovative adjunctive therapies – conceivably, Fusobacterium-targeted treatments or microbiome-based immunotherapies – aimed at improving survival in HNSCC. This study has several limitations that should be acknowledged. First, the number of eligible studies was relatively small, with only six studies included in the qualitative synthesis and five in the quantitative meta-analysis, which may limit the generalizability and statistical power of the findings. Second, considerable methodological heterogeneity was observed across studies, including variation in F. nucleatum detection methods (e.g., qPCR, RNA sequencing, 16 S rRNA), cut-off definitions for bacterial abundance, and adjustment for confounders such as HPV status or smoking. Third, the observational nature of all included studies precludes causal inference, and residual confounding cannot be excluded despite multivariable adjustments in some cohorts. Fourth, limited geographic and ethnic diversity across included populations may restrict external validity. In addition, several potentially relevant reports could not be included because they did not provide extractable effect sizes or did not report F. nucleatum as a separate variable. Finally, due to the lack of individual patient data, subgroup analyses by tumor subsite, stage, or HPV status could not be robustly conducted. These limitations highlight the need for future prospective studies with standardized microbiome profiling protocols and comprehensive clinical annotation. Future research should prioritize the development of standardized and reproducible methods for F. nucleatum quantification—such as harmonized qPCR protocols, threshold definitions, and tissue sampling strategies—to enable comparability across studies. Large, multi-center prospective cohorts are also needed to validate the prognostic utility of F. nucleatum in diverse head and neck cancer subsites and across HPV-positive and HPV-negative populations. Additionally, integrating microbial profiling with immune and genomic signatures could help elucidate context-dependent mechanisms linking F. nucleatum to tumor progression. Ultimately, such efforts will support the translation of F. nucleatum from an emerging biomarker to a clinically actionable tool. Conclusions In conclusion, the findings of this meta-analysis provide a comprehensive and critical analysis indicating that Fusobacterium within HNSCC tumors is linked to better oncological outcomes in most contexts. Although the overall effect estimates were robust, the lack of sufficient studies restricted meta-regression and sensitivity analyses, potentially limiting the precision and generalizability of our findings. These constraints underline the need for future large-scale, well-characterized cohorts to enable more nuanced exploration of subgroup-specific associations. Furthermore, the outcomes highlight a fascinating, complex relationship between the microbiome and cancer – one that merits deeper investigation for its biological significance and potential translational application. Supplementary Information Supplementary material 1. Supplementary material 1.